3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
26
Glioblastoma
25
Gliosarcoma
22
Rhabdomyosarcoma
21
Sarcoma, Ewing
18
Glioma
15
Brain Neoplasms
14
Astrocytoma
13
Neuroblastoma
12
Central Nervous System Neoplasms
12
Oligodendroglioma
9
Osteosarcoma
8
Neoplasms
7
Medulloblastoma
6
Pancreatic Neoplasms
5
Neuroectodermal Tumors, Primitive, Peripheral
5
Neoplasm Metastasis
5
Breast Neoplasms
5
Colorectal Neoplasms
4
Bone Neoplasms
4
Stomach Neoplasms
3
Recurrence
3
Optic Nerve Glioma
3
Malignant mesenchymal tumor
3
Diffuse Intrinsic Pontine Glioma
3
Colonic Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Rhabdoid Tumor
2
Interventions
mifamurtide
1
Temozolomide
1
Irinotecan
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Bone Tissue
×
Irinotecan
×
Sarcoma
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts